Search - tctmd.com

Displaying 861 - 880 of 1514

Sort: Relevancy | Date

Presentation TCT 2014

Delayed coverage of drug eluting stents after interventional revascularization of chronic total occlusions assessed by optical coherence tomography: the ALSTER-OCT-CTO registry

Presenter: Christian Heeger

September 16, 2014

Presentation TCT 2014

Regular Drug-Eluting Stent Versus Dedicated Bifurcation Sirolimus-Eluting BiOSS LIM® Stent In Coronary Bifurcation Treatment ? Randomized POLBOS II Study_

Presenter: Jacek Bil

September 16, 2014

Presentation TCT 2014

Two-Year Clinical Outcome of Patients With Implantation of Second-Generation Drug-Eluting Stents in the Right Coronary Ostium in the TWENTE Trial

Presenter: Ming Kai Lam

September 16, 2014

Presentation TCT 2014

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Presenter: Giulio Stefanini

September 16, 2014

Presentation TCT 2014

Comparison of endothelialization and inflammation between thin- and thick-strut contemporary bioerodable polymer drug-eluting stents and thick-strut fully resorbable scaffolds i___

Presenter: Kazuyuki Yahagi

September 16, 2014

News Industry News

New All-Comers Study Compares Efficacy of Bioresorbable Vascular Scaffold to Best-in-Class Drug Eluting Stents

September 16, 2014

News Industry News

Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014

September 16, 2014

News Industry News

Medtronic Drug-Coated Balloon Shows Strong Clinical and Economic Benefit in Treatment of Peripheral Artery Disease

September 16, 2014

Presentation TCT 2014

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang

September 15, 2014

Presentation TCT 2014

Do Drug-Eluting Balloons Have Anything to Offer for Bifurcation Treatment? From Theory to Data

Presenter: Bernard R. Chevalier, Leif Thuesen, Ricardo A. Costa, Kenneth Chin

September 15, 2014

Presentation TCT 2014

TCT 181: A Comparative Prospective Analysis of a Drug-Eluting Stent with Biodegradable Polymer Versus a Drug-Eluting Stent with Permanent Polymer in Bifurcation Lesions

Presenter: Bernard R. Chevalier, Leif Thuesen, Ricardo A. Costa, Ran Kornowski

September 15, 2014

Presentation TCT 2014

TCT 652: Incidence and Predictors of Late Catch-up Phenomenon After Drug-Eluting Stent Implantation

Presenter: Alexandre Abizaid, Pieter C. Smits, Robert J. Gil, Masanobu Ohya

September 15, 2014

Presentation TCT 2014

TCT 270: Comparison Among a Drug-Eluting Balloon, Drug-Eluting Stent, and Plain Balloon Angioplasty for Treatment of In-Stent Restenosis: A Network Meta-analysis of 11 Randomized Controlled Trials

Presenter: John A. Bittl, Tullio Palmerini, Joo Myung Lee, MD

September 15, 2014

Presentation TCT 2014

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Antonio Colombo

September 15, 2014

Presentation TCT 2014

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Nikolaus Sarafoff

September 15, 2014

News Conference News TCT 2014

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

September 15, 2014

News Conference News TCT 2014

Post-discharge Bleeding Common, Predictive of Mortality After PCI

September 15, 2014

News Industry News

New Study Examines the Optimal Duration Time of Dual Anti-Platelet Therapy in Patients with Second-Generation Drug-Eluting Stents

September 15, 2014

News Industry News

New Study Evaluates “Triple Therapy” Regimens After Drug-Eluting Stenting in Patients Requiring Oral Anticoagulation

September 15, 2014

News Conference News TCT 2014

Less Mortality with Paclitaxel-Coated Balloon vs. Stent in DES Restenosis

September 15, 2014

Advertisement

Delayed coverage of drug eluting stents after interventional revascularization of chronic total occlusions assessed by optical coherence tomography: the ALSTER-OCT-CTO registry

Regular Drug-Eluting Stent Versus Dedicated Bifurcation Sirolimus-Eluting BiOSS LIM® Stent In Coronary Bifurcation Treatment ? Randomized POLBOS II Study_

Two-Year Clinical Outcome of Patients With Implantation of Second-Generation Drug-Eluting Stents in the Right Coronary Ostium in the TWENTE Trial

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Comparison of endothelialization and inflammation between thin- and thick-strut contemporary bioerodable polymer drug-eluting stents and thick-strut fully resorbable scaffolds i___

New All-Comers Study Compares Efficacy of Bioresorbable Vascular Scaffold to Best-in-Class Drug Eluting Stents

Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014

Medtronic Drug-Coated Balloon Shows Strong Clinical and Economic Benefit in Treatment of Peripheral Artery Disease

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Do Drug-Eluting Balloons Have Anything to Offer for Bifurcation Treatment? From Theory to Data

TCT 181: A Comparative Prospective Analysis of a Drug-Eluting Stent with Biodegradable Polymer Versus a Drug-Eluting Stent with Permanent Polymer in Bifurcation Lesions

TCT 652: Incidence and Predictors of Late Catch-up Phenomenon After Drug-Eluting Stent Implantation

TCT 270: Comparison Among a Drug-Eluting Balloon, Drug-Eluting Stent, and Plain Balloon Angioplasty for Treatment of In-Stent Restenosis: A Network Meta-analysis of 11 Randomized Controlled Trials

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

SECURITY: Six-Month DAPT Noninferior to 12 Months with Second-Generation DES

Post-discharge Bleeding Common, Predictive of Mortality After PCI

New Study Examines the Optimal Duration Time of Dual Anti-Platelet Therapy in Patients with Second-Generation Drug-Eluting Stents

New Study Evaluates “Triple Therapy” Regimens After Drug-Eluting Stenting in Patients Requiring Oral Anticoagulation

Less Mortality with Paclitaxel-Coated Balloon vs. Stent in DES Restenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content